RxDoctor Payments Data

Rakesh Vadde

Critical Care Medicine · Elk Grove Village, ILNPI 1366680845

Payments from drug & device makers

What this record shows

Pulmonx Corporation accounts for 65.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $1,044 and has fallen 75.4% since, to $257 in 2025.

$3,504in general payments, 2019–2025

Across 84 payments — averaging $41.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$2K
  • GSK$387
  • AstraZeneca$189
  • Takeda Pharmaceuticals U.S.A., Inc.$133
  • Regeneron Healthcare Solutions, Inc.$74
  • Sanofi$61
  • plus $357 from 11 others

What the payments were for

  • Travel & lodging$1,80552%
  • Food & beverage$1,69948%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,504 in reported general payments places this provider in the 80th percentile of 281 critical care medicine providers in Illinois.

See all critical care medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$43,416
Medicare patients
242
Services billed
574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$41,995
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$25,494
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$17,416
Breo ElliptaFluticasone/Vilanterol23$11,064
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,510
Albuterol Sulfate HfaAlbuterol Sulfate82$1,859
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$1,555
Ventolin HfaAlbuterol Sulfate14$992
Prednisone37$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$387$78,553130 claims
AstraZenecaBreztri Aerosphere$189$6,51011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 281 critical care medicine providers in Illinois.

Other critical care medicine in Elk Grove Village

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →